explore -WSS

explore

author：entertainment 2025-09-29 20:00:38 - browse：81546

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： St. Louis police protesters begin picking up checks in $4.9 million settlement

WSS

Congress considering partial increase for doctor pay in Medicare

Congress considering partial increase for doctor pay in Medicare

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Congress might make insulin pumps more accessible to the blind

Election results set back Medicaid expansion plans

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Many breast cancer patients receive more radiation than needed

Sports medicine is finally prioritizing gender equality

Tuberculosis patients need more than just free medication

Malaria cases in Florida and Texas: Here’s what you need to know

Ebola vaccine can save some who are already sick, per new study

Affirmative action in medical school literally saved lives

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Psychedelics group wrestles with new pharma identity

Report cites 'urgent' need to recruit more diverse clinical trial participants

explore

Kansas bar where gunfire wounded 9 last month closes permanently

Kansas bar where gunfire wounded 9 last month closes permanently

It was time to plan for my old age. If only I could stop crying

Sage considers ways to reduce costs following FDA rejection

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Kansas bar where gunfire wounded 9 last month closes permanently

focus

focus

leisure time

focus